Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Panuveitis Clinical Trial

Official title:

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02725177
• Other study ID #: Ocular Sarcoidosis 15-1072
• Status: Completed
• Phase: N/A
• Start date: July 2016
• Est. completion date: March 2022

Study information

• Verified date: November 2023
• Source: The Cleveland Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Description:

The initial treatment of ocular sarcoidosis usually relies on a combination of topical glucocorticoids and oral glucocorticoids, both of which are associated with significant ocular and systemic toxicities. Steroid-sparing therapies are limited by variable and unpredictable efficacy, prolonged time until clinical response, medication intolerance, and difficulties obtaining payor approval. As a result, it is not uncommon that treating physicians must choose between excessive glucocorticoid toxicity versus poor control of ocular inflammation. Ongoing ocular inflammation, in turn, leads to eventual visual loss and occasionally blindness. There is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in sarcoidosis uveitis. Adrenocorticotropic hormone, through activation of melanocortin receptors on leukocytes, can dampen immune responses through non-glucocorticoid dependent mechanisms. The proposed study will aim to define whether there is effectiveness for ACTHAR gel in these patients, delineate an effect dosing regimen, and provide information about the safety of this approach for moderate to severe ocular sarcoidosis. ACTHAR is a 39-amino acid peptide natural form of adrenocorticotropin hormone (ACTH) that was initially approved in 1952 by the FDA. It has since been approved for 19 indications including respiratory sarcoidosis, multiple sclerosis, and infantile spasms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: March 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Patient with sarcoidosis as defined by ATS/ERS/WASOG guidelines (American Thoracic Society/European Respiratory Society /World Association of Sarcoidosis and Other Granulomatous Diseases)
• Any posterior, intermediate or panuveitis of sufficient severity to warrant therapy, in the opinion of the treating physician --OR-- Anterior uveitis requiring 4 or more daily applications of topical corticosteroids to maintain control of inflammation, or uncontrolled with topical therapy
• Persistent disease activity (active uveitis) at the time of screening

Exclusion Criteria:

• Other cause for ocular inflammation
• Uncontrolled diabetes, hypertension, or other contra-indication to increased dosage of glucocorticoids
• Recent (less than 4 weeks) intra-ocular or intra-orbital steroid injection
• Escalation of immunosuppressive medications between screening and initiation of the study medication
• Severe extra-ocular sarcoidosis likely to require additional therapy (in the opinion of the investigator)
• Administration of an investigational medication for sarcoidosis within 3 months, or 5 half-lives, whichever is longer
• Have a history of any opportunistic infection within 6 months prior to screening
• Have any history of malignancy, except fully resected cutaneous squamous cell cancer or cutaneous basal cell cancer, or cervical carcinoma in-situ with a minimum of 5 years period without recurrence
• Severe other organ disease felt to be likely to lead to death within the next six months
• Unable to follow the study protocol, including the requisite travel and follow-up ocular testing
• Women of childbearing potential must be using adequate birth control measures (abstinence, hormonal contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must agree to continue such precautions, and not become pregnant or plan a pregnancy for 6 months after receiving their last treatment with study agent. Women of childbearing potential must test negative on a serum pregnancy test at screening.
• Breastfeeding women are excluded from participation

Related Conditions & MeSH terms

• Anterior Uveitis
• Iridocyclitis
• Ocular Sarcoidosis
• Panuveitis
• Sarcoidosis
• Uveitis
• Uveitis, Anterior

Intervention

Drug:
• Repository Corticotropin Injection
Treatment with ACTHAR Gel for 24 weeks Initial treatment with 80 units daily for ten days (induction phase) Maintenance treatment with 80 units twice weekly (maintenance phase)
• Repository Corticotropin Injection -Treatment Extension
24 open label extension permitted in subjects who respond to treatment

Locations

Country	Name	City	State
United States	Cleveland Clinical Foundation	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
The Cleveland Clinic	Mallinckrodt

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With Clinically Significant Improvement in Visual Acuity	The primary outcome was percentage of patients meeting at least one of the following variables 1) improved visual acuity, 2) resolution of intraocular inflammation, 3) ability to taper ocular or oral steroids by at least 50% or 4) reduction of cystoid macular edema, with no worsening of any single one and no need for additional sarcoidosis therapies at 24 weeks .	Measured at 24 weeks
Secondary	Percentage of Patients With Clinically Significant Improvement in the Resolution-intraocular Inflammation		Measured at 24 weeks
Secondary	Proportion of Patients Experiencing a Tapering of Ocular/Oral Steroids by at Least 50%		Measured at 24 weeks
Secondary	Proportion of Patients With a Clinically Significant Reduction-cystoid Macular Edema		Measured at 24 weeks